Persistence Market Research

Diabetic Nephropathy Market - Global Study on Diabetic Nephropathy Asia to Witness Highest Growth by 2020
Persistence Market Research
Global Diabetic Nephropathy Market will

reach $3,145.9 million in 2020: Persistence
Market Research
Persistence Market Research Released New Market Report Global Market Study on Diabetic
Nephropathy Market Asia to Witness Highest Growth by 2020,.The global diabetic
nephropathy market was valued at USD 2,262.2 million in 2014 and is expected to grow at a
CAGR of 5.6% from 2014 to 2020, to reach an expected value of USD 3,145.9 million in
2020.
Browse
the
full
Diabetic
Nephropathy
Market
report
at
http://www.persistencemarketresearch.com/market-research/diabetic-nephropathymarket.asp
Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant
complications in terms of mortality and morbidity for patients with diabetes. Globally, the
diabetic nephropathy market is witnessing significant growth due to increasing prevalence of
diabetes and obesity in different regions of the world. In addition, increasing R&D
investments in drug discovery and development and raising awareness about diabetes and
kidney-related disorders are also driving the growth of the market. However, stringent
regulatory requirements and longer approval time for drugs as well as the lack of
comprehensive therapeutic management for diabetic nephropathy are inhibiting the growth
of diabetic nephropathy market. The global diabetic nephropathy market is estimated at
USD 2,262.2 million in 2014. It is likely to grow at a CAGR of 5.6% from 2014 to 2020 to
reach USD 3,145.9 million in 2020.
In North America, various government programs are spreading awareness about diabetes
and related renal complications. For instance, the National Kidney Disease Education
Program, one of the major programs organized by the U.S. government, for increasing
awareness about the various kidney diseases. In addition, the number of diabetic patients
are also increasing in the region; according to the SciELO Public Health, approximately 35
million people were affected with diabetes mellitus in 2000 and this number is expected to
reach 64 million by 2025 in North America.
In Europe, rise in healthcare expenditure for diabetes treatment and increasing prevalence
of diabetes in the various part of Europe is boosting the growth of the European diabetic
nephropathy market. According to IDF, approximately 55.4 million people had diabetes in
2010 and the number is expected to reach 66.5 million by 2030 in Europe. According to the
IDF, healthcare expenditure for diabetes treatment was approximately USD 105.5 billion in
2010 and is expected to reach USD 124.6 billion by 2030 in Europe.
Asia represents the fastest growing region in the diabetic nephropathy market due to the
rise in a diabetic population in various countries such as Japan and the Southeast Asian
countries. According to the International Diabetes Federation (IDF), developing countries,
such as India and China, are expected to have the highest number of diabetes mellitus
patients compared to developed countries, such as the U.S. and Germany.
Sanofi is one of the leading players in the diabetic nephropathy market. Other major players
in diabetic nephropathy market include Eli Lilly and Company, Mitsubishi Tanabe Pharma
Corporation, Novartis AG, Pfizer, Inc., Abbott Laboratories, AbbVie, Inc., Bayer AG, Merck &
Co., Inc., Bayer AG and Reata Pharmaceuticals, Inc.
The global diabetic nephropathy market is segmented as follows:
Diabetic nephropathy market, by model of treatment
Disease Modifying Therapies
Angiotensin-Converting Enzyme Inhibitors
Angiotensin Receptor Blockers
Diuretics
Calcium Channel Blockers
Renin Inhibitors
Connective Tissue Growth Factor Inhibitors
Antioxidant Inflammation Modulator
Monocyte Chemoattractant Proteins Inhibitor
Endothelin-A Receptor Antagonist
G Protein-Coupled Receptors
Diabetic nephropathy market, by geography
North America
U.S.
Canada
Europe
Germany
France
U.K.
Asia
Japan
China
India
Rest of the World (RoW)
Market History:
Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications
in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized
by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as
macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise
in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D
investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and
Mitsubishi Tanabe Pharma is also driving the growth of the market. However, stringent regulatory
requirements and longer approval time for drugs as well as the lack of comprehensive therapeutic
management for diabetic nephropathy are inhibiting the growth of diabetic nephropathy market. The
global diabetic nephropathy market is estimated at USD 2,262.2 million in 2014. It is likely to grow at a
CAGR of 5.6% from 2014 to 2020 to reach USD 3,145.9 million in 2020.
North America has the largest market for the global diabetic nephropathy market. However, In terms of
growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest
growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic
nephropathy.
North American market is estimated at USD 931.0 million in 2014 and is expected to reach USD 1,302.0
million in 2020, growing at a CAGR of 5.7% from 2014 to 2020.
The global DMT market is estimated at USD 2,093.5 million in 2014 and is expected to reach USD
2,929.8 million in 2020, growing at a CAGR of 5.8% from 2014 to 2020.
Table of Content
Chapter 1 Preface
1.1 Report Description
1.2 Research Methodology
1.3 Assumptions
Chapter 2 Market Synopsis
Chapter 3 Porters Five Forces Analysis
3.1 Bargaining Power of Suppliers
3.2 Bargaining Power of Buyers
3.3 Threat of New Entrants
3.4 Threat of Substitutes
3.5 Intensity of Rivalry
Chapter 4 Industry Overview
4.1 Market Definition
4.2 Market Drivers
4.2.1 Increasing prevalence of diabetes
4.2.2 Globally rising obesity increasing the prevalence of diabetes
4.2.3 Increasing R&D investments in drug discovery and development
4.2.4 Rising awareness among people about diabetes and kidney-related disorders
4.3 Impact Analysis of Market Drivers
4.4 Market Restraints
4.4.1 Strict regulatory requirements and long approval time for drugs
4.4.2 Lack of comprehensive therapeutic management for diabetic nephropathy
4.5 Impact Analysis of Market Restraints
4.6 Market Trends
4.6.1 Increasing usage of combination therapy is gaining popularity in diabetic
nephropathy market
Chapter 5 Global Market Size and Forecast
Chapter 6 Market Size and Forecast by Mode of Treatment
6.1 Disease Modifying Therapies
6.1.1 Angiotensin-Converting Enzyme Inhibitors
6.1.2 Angiotensin Receptor Blockers
6.1.3 Diuretics
6.1.4 Calcium Channel Blockers
6.1.5 Renin Inhibitors
6.1.6 Connective Tissue Growth Factor Inhibitors
6.1.7 Antioxidant Inflammation Modulator
6.1.8 Monocyte Chemoattractant Proteins Inhibitor
6.1.9 Endothelin-A Receptor Antagonist
6.1.10 G Protein-Coupled Receptors
Chapter 7 Market Size and Forecast by Geography

7.1 North America
7.1.1 Scenario in the U.S.
7.1.2 Scenario in Canada
7.2 Europe
7.2.1 Scenario in Germany
7.2.2 Scenario in France
7.2.3 Scenario in the U.K.
7.3 Asia
7.3.1 Scenario in Japan
7.3.2 Scenario in China
7.3.3 Scenario in India
Chapter 8 Pipeline Drugs for Diabetic Nephropathy
8.1 Drugs Under Development for Diabetic Nephropathy
Chapter 9 Competitive Scenario
9.1 Competitive Benchmarking
Chapter 10 Company Profiles
10.1 Novartis AG
10.1.1 Company overview

10.1.2 Products and services
10.1.3 Financial performance
10.1.4 Key developments
10.2 Merck & Co., Inc.
10.3 Pfizer, Inc.
10.4 Abbott Laboratories

10.5 Sanofi
10.6 Eli Lilly and Company
10.6.2 Products and segments
10.7 Reata Pharmaceuticals, Inc.
10.8 Bayer AG
10

10.9 AbbVie, Inc.
10.10 Mitsubishi Tanabe Pharma Corporation
List of Tables
TABLE 1 Market Snapshot: Diabetic nephropathy market, 2014 and 2020
TABLE 2 Drivers for diabetic nephropathy market: Impact analysis
TABLE 3 Estimated average timelines for clinical trial approval in various countries
TABLE 4 Restraints for diabetic nephropathy market: Impact analysis
11
TABLE 5 Global diabetic nephropathy market size, by region, 2010 2013 (USD thousand)
TABLE 6 Global diabetic nephropathy market size, by region, 2014 2020 (USD thousand)
TABLE 7 Global diabetic nephropathy market size, by mode of treatment, 2010 2013 (USD
thousand)
TABLE 8 Global diabetic nephropathy market size, by mode of treatment, 2014 2020 (USD
thousand)
TABLE 9 Global DMT market size, by region, 2010 2013 (USD thousand)
TABLE 10 Global DMT market size, by region, 2014 2020 (USD thousand)
TABLE 11 Global DMT market size, by drug categories, 2010 2013 (USD thousand)
TABLE 12 Global DMT market size, by drug categories, 2014 2020 (USD thousand)
TABLE 13 Global ACE inhibitors market size, by region, 2010 2013 (USD thousand)
TABLE 14 Global ACE inhibitors market size, by region, 2014 2020 (USD thousand)
TABLE 15 Global ARBs market size, by region, 2010 2013 (USD thousand)
TABLE 16 Global ARBs market size, by region, 2014 2020 (USD thousand)
TABLE 17 Global diuretics market size, by region, 2010 2013 (USD thousand)
TABLE 18 Global diuretics market size, by region, 2014 2020 (USD thousand)
TABLE 19 Global CCBs market size, by region, 2010 2013 (USD thousand)
TABLE 20 Global CCBs market size, by region, 2014 2020 (USD thousand)
TABLE 21 Global renin inhibitors market size, by region, 2010 2013 (USD thousand)
12
TABLE 22 Global renin inhibitors market size, by region, 2014 2020 (USD thousand)
TABLE 23 Global CTGF inhibitors market size, by region, 2010 2013 (USD thousand)
TABLE 24 Global CTGF inhibitors market size, by region, 2014 2020 (USD thousand)
TABLE 25 Global AIM market size, by region, 2010 2013 (USD thousand)
TABLE 26 Global AIM market size, by region, 2014 2020 (USD thousand)
TABLE 27 Global MCP inhibitors market size, by region, 2010 2013 (USD thousand)
TABLE 28 Global MCP inhibitors market size, by region, 2014 2020 (USD thousand)
TABLE 29 Global ETAR market size, by region, 2010 2013 (USD thousand)
TABLE 30 Global ETAR market size, by region, 2014 2020 (USD thousand)
TABLE 31 Global GPCRs market size, by region, 2010 2013 (USD thousand)
TABLE 32 Global GPCRs market size, by region, 2014 2020 (USD thousand)
TABLE 33 The North American diabetic nephropathy market size, by country, 2010 2013
(USD thousand)
TABLE 34 The North American diabetic nephropathy market size, by country, 2014 2020
(USD thousand)
TABLE 35 The U.S. diabetic nephropathy market size, by mode of treatment, 2010 2013
(USD thousand)
TABLE 36 The U.S. diabetic nephropathy market size, by mode of treatment, 2014 2020
(USD thousand)
13
TABLE 37 The Canadian diabetic nephropathy market size, by mode of treatment, 2010
2013 (USD thousand)
TABLE 38 The Canadian diabetic nephropathy market size, by mode of treatment, 2014
2020 (USD thousand)
TABLE 39 The European diabetic nephropathy market size, by country, 2010 2013 (USD
thousand)
TABLE 40 The European diabetic nephropathy market size, by country, 2014 2020 (USD
thousand)
TABLE 41 The German diabetic nephropathy market size, by mode of treatment, 2010
2013 (USD thousand)
TABLE 42 The German diabetic nephropathy market size, by mode of treatment, 2014
2020 (USD thousand)
TABLE 43 The French diabetic nephropathy market size, by mode of treatment, 2010 2013
(USD thousand)
TABLE 44 The French diabetic nephropathy market size, by mode of treatment, 2014 2020
(USD thousand)
TABLE 45 The U.K. diabetic nephropathy market size, by mode of treatment, 2010 2013
(USD thousand)
TABLE 46 The U.K. diabetic nephropathy market size, by mode of treatment, 2014 2020
(USD thousand)
TABLE 47 The Asian diabetic nephropathy market size, by country, 2010 2013 (USD
thousand)
TABLE 48 The Asian diabetic nephropathy market size, by country, 2014 2020 (USD
thousand)
14
TABLE 49 The Japanese diabetic nephropathy market size, by mode of treatment, 2010
2013 (USD thousand)
TABLE 50 The Japanese diabetic nephropathy market size, by mode of treatment, 2014
2020 (USD thousand)
TABLE 51 The Chinese diabetic nephropathy market size, by mode of treatment, 2010 2013
(USD thousand)
TABLE 52 The Chinese diabetic nephropathy market size, by mode of treatment, 2014 2020
(USD thousand)
TABLE 53 The Indian diabetic nephropathy market size, by mode of treatment, 2010 2013
(USD thousand)
TABLE 54 The Indian diabetic nephropathy market size, by mode of treatment, 2014 2020
(USD thousand)
TABLE 55 Major pipeline drugs for diabetic nephropathy
TABLE 56 Product categories of Novartis AG
TABLE 57 Product categories of Merck & Co., Inc.
TABLE 58 Product categories of Pfizer, Inc.
TABLE 59 Product categories of Abbott Laboratories
TABLE 60 Product categories of Sanofi
TABLE 61 Product segments of Eli Lilly and Company
TABLE 62 Product categories of Reata Pharmaceuticals, Inc.
TABLE 63 Product categories of Bayer AG
15
TABLE 64 Product categories of AbbVie, Inc.
TABLE 65 Product categories of Mitsubishi Tanabe Pharma Corporation
List of Figures
FIG. 1 Diabetic nephropathy market: Porters five forces analysis
FIG. 2 Major DMT for diabetic nephropathy
FIG. 3 Number of people with diabetes mellitus (20 79 years) in major countries, 2010, and
2030 (million)
FIG. 4 Prevalence of overweight and obese males aged 30 years and above, 2005 and 2015
(%)
FIG. 5 Prevalence of overweight and obese females aged 30 years and above, 2005 and
2015 (%)
FIG. 6 Global diabetic nephropathy market share, by region, by value, 2013
FIG. 7 Global diabetic nephropathy market share, by mode of treatment, by value, 2013
FIG. 8 Global DMT market share, by region, by value, 2013 30
FIG. 9 Global DMT market share, by disease categories, by value, 2013
FIG. 10 Global ACE inhibitors market share, by region, by value, 2013
FIG. 11 Global ARBs market share, by region, by value, 2013
FIG. 12 Global diuretics market share, by region, by value, 2013
FIG. 13 Global CCBs market share, by region, by value, 2013
FIG. 14 Global renin inhibitors market share, by region, by value, 2013
16
FIG. 15 Global CTGF inhibitors market share, by region, by value, 2013

FIG. 16 Global AIM market share, by region, by value, 2013
FIG. 17 Global MCP inhibitors market share, by region, by value, 2013
FIG. 18 Global ETAR market share, by region, by value, 2013
FIG. 19 Global GPCRs market share, by region, by value, 2013
FIG. 20 The North American diabetic nephropathy market share, by country, by value, 2013
FIG. 21 The U.S. diabetic nephropathy market share, by mode of treatment, by value, 2013
FIG. 22 The Canadian diabetic nephropathy market share, by mode of treatment, by value,
2013
FIG. 23 The European diabetic nephropathy market share, by country, by value, 2013
FIG. 24 The German diabetic nephropathy market share, by mode of treatment, by value,
2013
FIG. 25 The French diabetic nephropathy market share, by mode of treatment, by value,
2013
FIG. 26 The U.K. diabetic nephropathy market share, by mode of treatment, by value, 2013
FIG. 27 The Asian diabetic nephropathy market share, by country, by value, 2013
FIG. 28 The Japanese diabetic nephropathy market share, by mode of treatment, by value,
2013
FIG. 29 The Chinese diabetic nephropathy market share, by mode of treatment, by value,
2013
17
FIG. 30 The Indian diabetic nephropathy market share, by mode of treatment, by value,
2013
FIG. 31 Competitive landscape of diabetic nephropathy market, 2013
FIG. 32 Novartis AGs net sales and net income, 2011 2013 (USD million)
FIG. 33 Merck & Co., Inc.s sales and net income, 2011 2013 (USD million)
FIG. 34 Pfizer, Inc.s revenue and net income, 2011 2013 (USD million)
FIG. 35 Abbott Laboratories net sales and net earnings, 2011 2013 (USD million)
FIG. 36 Sanofis net sales and net income, 2011 2013 (USD million)
FIG. 37 Eli Lilly and Companys revenue and net income, 2011 2013 (USD million)
FIG. 38 Bayer AGs net sales and net income, 2011 2013 (USD million)
FIG. 39 AbbVie, Inc.s net sales and net earnings, 2011 2013 (USD million)
FIG. 40 Mitsubishi Tanabe Pharma Corporations net sales and net earnings, 2011 2013
(USD million)
About Us:
Persistence Market Research is a global market research firm specializing- syndicated research,
custom research, and consulting services
At Persistence Market Research (PMR), we are in the business of accelerating your business. As a fullservice market research firm, we stand committed to bringing more accuracy and speed to your business
decisions. From ready-to-purchase market research reports to customized global research solutions, our
engagement models are highly flexible without compromising on our deep-seated research values. Briefly
stated, our mission is to give you access to forecasts and trends analyses that put you on the path to
profitability.
18
PMRs Services Go Beyond Gleaning Data
Most enterprises believe that IT and databases are enough to make an accurate decision. While we do
not dispute that, consider this: How long does it take to make an accurate and strategic million-dollar
decision? We strive to deliver both even with demanding deadlines.
Contact Us:
Addie Thomes
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
19

Persistence Market Research

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Persistence Market Research

Uploaded by

Copyright:

Available Formats

Diabetic Nephropathy Market - Global Study on Diabetic Nephropathy Asia to Witness Highest Growth by 2020